Cancer biomarkers are biomolecules that specifies the existence of cancer or cancerous cells in the body. These are generally molecules that are released due to the presence of a tumor or a particular indication in the body to the presence of cancer. These molecules are densely distributed in tissues, urine, serum, blood, and other body fluids. Their expression levels serve as the basis or indication of any abnormal process or a disease.
The market size of the global cancer biomarkers market was valued at $6,521 million in 2015 and is estimated to grow at a CAGR of 13% over the forecast period to reach $15,737 million in 2022. Market growth is attributed to the increasing incidences of cancers such as lung cancer, breast cancer, and prostate cancer among others coupled with growing importance of biological and targeted drug therapies and technological advancements in the field of cancer treatment. However, unregulated government laws and reimbursement policies; as well as high cost of drug development and threat of failure are anticipated to have an adverse effect on the market growth. Nevertheless, advancement in cancer drugs research and significant unmet need in cancer diagnosis are estimated to overshadow these restraints.
The global cancer biomarkers market is segmented based on profiling technology, biomolecules, cancer type, application, and geography. By profiling technology, the market is segmented into omic technologies, imaging technologies, immunoassays and cytogenetics based tests. Based on biomolecules, the market is segmented into genetic biomarkers, protein biomarkers, and glycoprotein biomarkers. Amongst these, genetic biomarkers are widely used in the market owing to better diagnostic and therapeutic usage as compared to protein and glycoprotein biomarkers.
The various cancer types include breast cancer, lung cancer, prostate cancer, colorectal cancer, stomach cancer, and others. Amongst these, lung cancer is the major cancer type where biomarkers are being used for detection. Owing to high tobacco consumption and smoking, lung cancer has increased at an alarming rate. CEACAM-5/CD66e, Cytokeratin 19, EGF R/ErbB1, Enolase 2/Neuron-specific Enolase, Lactate Dehydrogenase A/LDHA, Lactate Dehydrogenase B/LDHB, Napsin A and PDGFRL are some of the major cancer biomarkers used for lung cancer detection.
Geographically, North America is the leading revenue generating region, due to high incidence rate of cancer, growth in awareness towards cancer and higher cancer biomarker testing. Asia-Pacific is growing at the fastest CAGR due to rise in awareness, increased disposable income, and affordability for advanced cancer treatments.
Companies have adopted collaboration and partnership as their key development strategies. Increase in focus on collaboration and partnership is mainly for the development of innovative technologies in the field of cancer biomarkers. In May 2016, Roche received an approval by FDA for its first anti-PD-L1 cancer immunotherapy namely Tecentriq (atezolizumab), thereby expanding its product portfolio.
KEY BENEFITS FOR STAKEHOLDERS:
The drivers, restraints, and opportunities in the global cancer biomarkers market are expected to help in understanding the market behavior better.
The market estimations are a result of high-end analysis of the key market segments for the period of 2014–2022
Projections in the report are made by analyzing the current market trends and future market potential for the forecast period in terms of value. The analysis helps in understanding the strategies adopted by various companies for the growth of the global cancer biomarkers market.
Country level analysis has been done to provide micro market sizing of cancer biomarkers in different regions
Porter's five forces model gives an in-depth analysis of bargaining power of buyers and suppliers, threats of new entrants & substitutes, and competition amongst the key market players.
KEY MARKET SEGMENTS:
By Profiling Technology
Cytogenetics Based Tests
By Cancer Type
Drug Discovery and Development
Rest of Europe
Rest of Asia-Pacific
Rest of LAMEA
1.1 Report description
1.2 Key benefits
1.3 Key market segments
1.4 Research methodology
1.4.1 Secondary research
1.4.2 Primary research
1.4.3 Analyst tools and models
CHAPTER 2 EXECUTIVE SUMMARY
2.1 CXO perspective
CHAPTER 3 MARKET OVERVIEW
3.1 Market definition and scope
3.2 Biomarker diagnosis vs. conventional diagnosis
3.3 Key findings
22.214.171.124 Rise in incidence and prevalence of various cancer types
126.96.36.199 Growth in importance of biological and targeted drug therapies
188.8.131.52 Expiration of key patents and biosimilars impact
184.108.40.206 Increase in acquisitions and collaborations
220.127.116.11 Technological advancements
18.104.22.168 Accuracy and reliability
22.214.171.124 Rise in investment from government, public, and private sectors
126.96.36.199 Increase in clinical trials
188.8.131.52 Growth in popularity of personalized medicine and companion diagnostics
184.108.40.206 High cost of drug development and threat of failure
220.127.116.11 Unregulated government regulation and reimbursement policies
18.104.22.168 Adverse effects of cancer drug therapy
22.214.171.124 Advancement of cancer drugs research
126.96.36.199 Increased focus towards advanced treatment protocols
188.8.131.52 Significant unmet need in cancer diagnosis
184.108.40.206 Increased awareness to reduce healthcare costs
220.127.116.11 Opportunities in emerging economies
3.3.4 Top investment pockets
3.3.5 Top winning strategies
3.4 Porters five forces analysis
3.4.1 High bargaining power of suppliers
3.4.2 Low bargaining power of buyers
3.4.3 High threat from substitutes
3.4.4 Low threat of new entrants
3.4.5 High intensity of competitive rivalry
3.5 Top player positioning, 2015
3.6 Patent analysis
3.6.1 U.S. patent analysis by market participant
3.6.2 Europe patent analysis by market participant
3.6.3 China patent analysis by market participant
3.6.4 Canada patent analysis by market participant
3.6.5 Japan patent analysis by market participant
3.6.6 Other countries patent analysis by market participant
3.7 Clinical trials
CHAPTER 4 CANCER BIOMARKERS MARKET, BY PROFILING TECHNOLOGY, 2014-2022
4.1.1 Market size and forecast
4.1 Omic technologies
4.1.1 Key market trends
4.1.2 Key growth factors and opportunities
4.1.3 Market size and forecast
18.104.22.168 Market size and forecast
22.214.171.124 Next-generation sequencing (NGS)
126.96.36.199 Polymerase chain reaction (PCR)
188.8.131.52 Market size and forecast
184.108.40.206 Mass spectrometry
220.127.116.11D gel electrophoresis
18.104.22.168 Protein microarray technology
22.214.171.124 Antibody array technology
126.96.36.199 Peptide array technology
4.1.6 Other omic technologies
188.8.131.52 Market size and forecast
4.2 Imaging technologies
4.2.1 Key market trends
4.2.2 Key growth factors and opportunities
4.2.3 Market size and forecast
4.2.4 Magnetic resonance imaging
4.2.5 Positron emission tomography
4.2.6 Computed tomography
4.3.1 Key market trends
4.3.2 Key growth factors and opportunities
4.3.3 Market size and forecast
4.3.4 Immunohistochemistry tests
4.3.5 Enzyme-linked immunosorbent assay
4.3.6 Flow cytometry
4.4 Cytogenetics-based tests
4.4.1 Key market trends
4.4.2 Key growth factors and opportunities
4.4.3 Market size and forecast
4.4.4 In situ hybridization
4.4.5 Others (karyotyping, amplichip, and in vitro diagnostic multivariate index assays [IVDMIA])
CHAPTER 5 GLOBAL CANCER BIOMARKERS MARKET, BY BIOMOLECULE (2014-2022)
5.1.1 Market size and forecast
5.2 Genetic biomarkers
5.2.1 Market size and forecast
5.3 Protein biomarkers
5.3.1 Market size and forecast
5.4.1 Market size and forecast
CHAPTER 6 CANCER BIOMARKERS MARKET, BY CANCER TYPE, 2014-2022
6.1.1 Market size and forecast
6.2 Lung cancer
6.2.1 Market size and forecast
6.3 Breast cancer
6.3.1 Market size and forecast
6.4 Colorectal cancer
6.4.1 Market size and forecast
6.5 Prostate cancer
6.5.1 Market size and forecast
6.1 Stomach cancer
6.1.1 Market size and forecast
6.2.1 Market size and forecast
CHAPTER 7 CANCER BIOMARKERS MARKET, BY APPLICATION, 2014-2022
7.1.1 Market size and forecast
7.2.1 Market size and forecast
7.3 Drug discovery and development
7.3.1 Market size and forecast
7.4.1 Market size and forecast
7.5 Risk assessment
7.5.1 Market size and forecast
7.6 Others (personalized medicine, surrogate endpoints, recurrence, and therapeutics)
7.6.1 Market size and forecast
CHAPTER 8 CANCER BIOMARKERS MARKET BY GEOGRAPHY, 2014-2022
8.1.1 Market size and forecast
8.2 North America
8.2.1 Key market trends
8.2.2 Growth factors and opportunities
8.2.3 Market size and forecast
184.108.40.206 U.S.: market size and forecast
220.127.116.11 Canada: market size and forecast
18.104.22.168 Mexico: market size and forecast
8.3.1 Key market trends
8.3.2 Growth factors and opportunities
8.3.3 Market size and forecast
22.214.171.124 Germany: market size and forecast
126.96.36.199 UK: market size and forecast
188.8.131.52 France: market size and forecast
184.108.40.206 Italy: market size and forecast
220.127.116.11 Russia: market size and forecast
18.104.22.168 Rest of Europe: market size and forecast
8.4.1 Key market trends
8.4.2 Key growth factors and opportunities
8.4.3 Market size and forecast
22.214.171.124 Japan: market size and forecast
126.96.36.199 China: market size and forecast
188.8.131.52 India: market size and forecast
184.108.40.206 Australia: market size and forecast
220.127.116.11 Rest of Asia-Pacific: market size and forecast
8.5 LAMEA (Latin America, Middle East, and Africa)
8.5.1 Key market trends
8.5.2 Key growth factors and opportunities
18.104.22.168 Brazil: market size and forecast
22.214.171.124 Saudi Arabia: market size and forecast
126.96.36.199 UAE: market size and forecast
188.8.131.52 Rest of LAMEA: market size and forecast
CHAPTER 9 COMPANY PROFILES
9.1 F. Hoffmann-La Roche Ltd.
9.1.1 Company overview
9.1.2 Business performance
9.1.3 Key strategies and developments
9.2 Abbott Laboratories
9.2.1 Company overview
9.2.2 Company Snapshot
9.2.3 Operating business segments
9.2.4 Business performance
9.2.5 Key strategies & developments
9.3 GlaxoSmithKline plc
9.3.1 Company overview
9.3.2 Operating business segments
9.3.3 Business performance
9.3.4 Key strategies and developments
9.4 Novartis AG
9.4.1 Company overview
9.4.2 Operating business segments
9.4.3 Business performance
9.4.4 Key strategies and developments
9.5 Merck & Co., Inc.
9.5.1 Company overview
9.5.2 Company snapshot
9.5.3 Operating business segments
9.5.4 Business performance
9.5.5 Key strategies and developments
9.6 Bristol-Myers Squibb
9.6.1 Company overview
9.6.2 Company snapshot
9.6.3 Business performance
9.6.4 Key strategies and developments
9.7 Eli Lilly and Company
9.7.1 Company overview
9.7.2 Company snapshot
9.7.3 Operating business segments
9.7.4 Business performance
9.7.5 Key strategies and developments
9.8 Pfizer, Inc.
9.8.1 Company overview
9.8.2 Company snapshot
9.8.3 Operating business segments
9.8.4 Business performance
9.8.5 Key strategies and developments
9.9 Qiagen N.V.
9.9.1 Company overview
9.9.2 Company snapshot
9.9.3 Key strategy move and development
9.10 Genomic Health, Inc.
9.10.1 Company overview
9.10.2 Company snapshot
9.10.3 Business performance
9.10.4 Key strategies and developments
The market for cancer biomarkers is primarily driven by rise in prevalence of cancer cases, growing importance of biological & targeted drug therapies, technological advancements, and accuracy & reliability of cancer biomarkers for cancer detection. Moreover, rise in investments from government, public & private sector for biomarker research and technological advancements for cancer diagnostics have a positive impact on the market. However, high cost of drug development, threat of failure, and unregulated government regulations & reimbursement policies could restrain the market. Yet, the impact of these limitations is anticipated to reduce due to substantial surge in cancer diagnosis as well as increased focus towards advanced treatment protocols.
In terms of applications, diagnostics accounted for major share of the global cancer biomarkers market in 2015, and is projected to maintain this trend throughout the forecast period growing at a CAGR of 14%.
In terms of profiling technology, omic technology is the most popular and conventional method for biomarker detection and is projected to grow at a CAGR of 12%. However, immunoassays segment is anticipated to experience higher adoption rate, majorly due to the increase in use of flow cytometry, and is expected to grow at a CAGR of 18% during the forecast period.
In the year 2015, genetic biomarkers accounted for highest revenue share and is expected to grow at a CAGR of 13% during the forecast period. The use of genetic biomarkers for detecting gene mutations and gene expressions is expected to drive the growth of the biomolecule. However, use of glyco biomarkers due to better identification of cancerous gene is further expected to increase the segment growth which is expected to grow by 14% during the forecast period.
Key Findings of the Cancer Biomarkers Market:
Immunoassays are projected to be the fastest growing segment, growing at a CAGR of 18% during the forecast period.
Omic technologies is anticipated to be the highest revenue generating segment followed by imaging technologies during 20162022.
In the year 2015, genetic biomarkers was the leading segment and is projected to grow at a CAGR of 13%.
Use of protein biomarkers was highest in North America, covering approximately 37% of the global market share in 2015.
Europe accounted for approximately one-third of the global cancer biomarkers market in 2015.
Asia-Pacific is estimated to be the fastest growing region in cancer biomarkers market, growing at a CAGR of 14%.
Mexico is projected to be the fastest growing country in the North America region growing at a CAGR of 13% during the forecast period.
China and Japan were the leading markets for cancer biomarkers in the Asia-Pacific region covering three-fifth of the total market in 2015.
North America dominated the global cancer biomarkers market. This is primarily attributed to the biomarker discoveries resulting from technological advancements. Moreover, rise in awareness about cancer as well as availability of better treatment facilities has also fueled the market growth. Europe and Asia-Pacific together accounted for around half of the market in 2015.
The companies adopted collaboration and partnership as their prime strategy to keep pace with the changing demands of consumers and strengthen their market position. The key players for this market include F.Hoffmann-La Roche Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis AG, Merck & Co., Inc., Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, Inc., Qiagen N.V. and Genomic Health, Inc.
The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.
They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.
They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:
- Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
- Scientific and technical writings for product information and related preemptions
- Regional government and statistical databases for macro analysis
- Authentic news articles and other related releases for market evaluation
- Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast
Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.